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Available online 18 May 2016Objective: LOX-Index is a novel biomarker for cardiovascular disease (CVD) and is calculated bymultiplying LOX-
1 ligands containing apolipoprotein B (LAB) and soluble LOX-1 (sLOX-1). The Framingham risk score (FRS) is a
common clinical tool for risk assessment of coronary artery disease. Mental stress can also be an important
risk factor for CVD. The purpose of this study was to examine the relationship between LOX-Index and FRS or
mental stress.
Methods: LOX-Index was measured in 453 subjects including 150 consecutive outpatients with lifestyle-related
diseases such as diabetes, hyperlipidemia, and hypertension and 303 healthy volunteers. Mental stress was eval-
uated by the Self-Rating Depression Scale (SDS).
Results: LOX-Index was signiﬁcantly related with the 10-years risk of FRS. Multiple regression analysis demon-
strated that LAB was closely associated with the smoking status, low-density lipoprotein (LDL), and high-
density lipoprotein (HDL). There were no signiﬁcant associations between LOX-Index and the SDS scores;
however, by simultaneously using LOX-Index and SDS, the subjects could be classiﬁed in terms of oxidative stress
and mental stress.
Conclusions: LOX-Index appears to be a comprehensivemarker that could evaluate the status ofmultiple CVD risk
factors. The classiﬁcation with LOX-Index and SDS could contribute to the risk assessment for CVD.
© 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Mental stress1. Introduction
Atherosclerosis-based cardiovascular disease (CVD) is still a major
cause of death in developed countries, including Japan. Furthermore,
Karoshi, death from over-work, is a pressing societal issue in Japan and
it is usually the extreme result of CVD. The pathogenesis of CVD is a
complicated process; however, recent research has revealed that re-
sponses to various types of stress including mental stress and oxidative
stress play an important role in the pathogenesis of these diseases.
There has been growing accumulating evidences that well-known ath-
erosclerotic risk factors such as hypertension, diabetes, hyperlipidemia,
and smoking can induce oxidative stress in the cardiovascular system.
Under enhanced oxidative stress, low-density lipoprotein (LDL) is oxi-
datively modiﬁed. The formed oxidized LDL induces various biological
activities that are related to atherosclerotic processes. Oxidized LDL
causes endothelial dysfunction, promotes the proliferation of vascular
smooth muscle cells, and induces the expression of adhesion moleculesar Disease, Kobe Rosai Hospital,
e).
land Ltd. This is an open access articland chemokines [1–3]. These pathophysiological effects are mainly
mediated via LOX-1 [4,5]. Recently, the Suita cohort investigation has
revealed that a higher LOX-index, in which the LOX-1 ligands contain-
ing apolipoprotein B (LAB) and soluble LOX-1 (sLOX-1) were multi-
plied, was associated with an increased risk of CVD and stroke [6].
Thus, LOX-Index might be a novel predictive marker for these diseases
from the standpoint of oxidative stress.
There have been numerous studies that have indicated an etiological
association betweenmental stress and the development of CVD [7]. The
mechanisms by which mental stress or depression induces and exacer-
bates CVD remain unclear; however, the sympathetic nervous systemor
the hypothalamic–pituitary–adrenal axis might be involved. Recent re-
search has indicated that mental exacerbationmight be associatedwith
the oxidative stress. For example, the production of reactive oxygen
species (ROS) has been enhanced under high mental stress in both an-
imals and humans. Depressive symptoms have been correlated with
lipid peroxidation in human blood [8]. Andersson et al. investigated
the effects of psychological stress on LOX-1 expression in rats [9].
Psychological stress upregulated LOX-1 levels in the vessel wall in by
psychological stress through the formation of ROS. Their experimental
observations suggested the possibility that LOX-1 might be a key mole-
cule that linked inking oxidative stress and mental stress.e under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Patient characteristics.
Patients characteristics
Age, mean (SD), y 54.1 9.85
Male sex, no. (%) 257 56.7
Diabetes no. (%) 54 11.9
Hypertension no. (%) 114 25.2
Hyperlipidemia no. (%) 115 25.4
Current smokers no. (%) 51 11.3
LOX-Index, mean (SD) 985.0 420.5
sLOX-1, mean (SD), μg/mL 351.0 119.6
LAB, mean (SD), μg/mL 2.83 0.76
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tool for the assessment of the risk for coronary artery disease as well as
in the identiﬁcation of individuals who were candidates for risk factors
modiﬁcations [10]. The FRS is based on sex and age stratiﬁed tableswith
speciﬁc scores assigned for LDL and high-density lipoprotein (HDL)
cholesterol levels, smoking status, and systolic blood pressure. In the
present study, the relationship between LOX-Index and the FRS was ex-
amined in outpatients with lifestyle-related diseases such as diabetes,
hyperlipidemia, and hypertension and in healthy volunteers. Further-
more, we also examined the relationship of LOX-Index and mental
stress as assessed by the Self-Rating Depression Scale (SDS).
2. Method
2.1. Subjects
Between May 2014 and June 2015, 453 subjects including 150
consecutive outpatients with lifestyle-related diseases and 303 healthy
volunteers were recruited for the present study. The purpose of
the present study was explained to the participants in the documents,
and written informed consent was obtained from all participants. The
present study was approved by the ethics committee of Kobe Rosai
Hospital.
All enrolled patients were interviewed and clinically examined. De-
mographic information (age and sex) andmedical history were record-
ed. Hypertension was deﬁned as a systolic pressure ≥140 mm Hg or a
diastolic pressure ≥90 mm Hg, or if antihypertensive drugs were used.
Dyslipidemia was deﬁned as plasma LDL ≥ 140mg/dL, plasma triglycer-
ides (TG) ≥ 150 mg/dL, or plasma HDL b 40 mg/dL or if lipid-lowering
drugs were used. Diabetes mellitus was deﬁned as previous or current
plasma fasting glucose ≥126mg/dl or if hypoglycemic agentswere used.
2.2. Measurement of LOX-Index
All measurements of LOX-Index were performed at NK Medico Co
(Tokyo, Japan) similar to the previous investigation [6,11]. In brief, the
recombinant LOX-1 was immobilized on plates, and the serum LAB
levels were measured by sandwich chemiluminescent enzyme immu-
noassay (CLEIA) using recombinant sLOX-1 and monoclonal antibody
against the extracellular domain of apolipoprotein (ApoB), that is, a
chicken monoclonal anti-human ApoB antibody HUC20. This assay sys-
tem canmeasure the levels of LAB in the serum, such as VLDL remnants
or oxidized LDL [12]. The plasma levels of sLOX-1 were measured by
sandwich CLEIA using two kinds of monoclonal antibodies against the
extracellular domain of LOX-1, that is, B017M and a chickenmonoclonal
anti-human LOX-1 antibody HUC3–48.
2.3. Evaluation of depression by the Self-Rating Depression Scale
The SDS designed by Zung was used to quantify the depression level
who had experienced depression-related symptoms [12]. Among the
enrolled subjects, 331 participants agreed to the evaluation of their
mental status using SDS. The SDS included 10 positively worded items
and 10 negatively worded items that assess the symptoms of depres-
sion. The item responses were rated from 1 to 4, and higher scores cor-
respond to more frequent symptoms. Therefore, for each item, patients
give a score according to whether the item has occurred: 1 = never/
very rarely/rarely; 2 = once in a while/some of the time/occasionally;
3 = relatively often/very often/often; 4 = most of the time/always/
almost always. The SDS scores were used to deﬁne the following four
categories of depression severity: within the normal range (below 40
points); presence of minimal to mild depression (40–47 points); pres-
ence of moderate to marked depression (48–55 points); and presence
of severe to extreme depression (56 points and above). In the present
study, the subjects who had scores over 40 points were deﬁned as
being depressed.2.4. Calculation of the Framingham risk score
The FRS is based on sex- and age-stratiﬁed tableswith speciﬁc scores
assigned for total andHDL cholesterol levels, smoking status, and systol-
ic blood pressure (untreated and treated) and also provides an estimate
for the 10-year risk of developing cardiovascular disease [11]. The FRS
was calculated using a computer program, which took age, sex, LDL-
cholesterol, HDL cholesterol, systolic and diastolic blood pressure,
smoking and the presence of diabetes into account.
2.5. Statistical analysis
The continuous data are described as the mean and standard devia-
tion (SD). The categorical variables are displayed as number (percent-
age). The LAB, sLOX-1 and TG levels were log-transformed for all of
the regression analyses. Multiple linear regression analyses were used
to explore the relationships between variables. Standardized coefﬁcient
and 95% conﬁdence interval (CI) were calculated.
To evaluate the collinearity between variables, the variance inﬂation
factor (VIF) was estimated. If the estimated VIF for one variable is over
10, there is strong possibility of the existence of collinearity. The statis-
tical analyses were performed using IBM SPSS Statistics Version 22 or
the GraphPad Prism version 5. A p-value of b0.05was considered statis-
tically signiﬁcant.
3. Results
3.1. Association of LOX-Index with FRS
A total of 453 subjects were enrolled in this study, and their charac-
teristics are shown in Table 1. Fig. 1 is a histogram for LOX-Index and
log-converted LOX-Index in men and women. The LOX-Index in the
enrolled subjects was distributed from 310 to 3728 in a wide range.
After log conversion, LOX-Index had normal distribution (Kolmogorov–
Smirnov test: p b 0.001 for LOX-Index and p = 0.200 for log-converted
LOX-Index).
The relationship between the 10-year risk of FRS and the log-
converted LOX-Index was examined in these subjects. As shown in
Fig. 2, there were signiﬁcant positive correlation between the 10-year
risk of FRS and the log-converted LOX-Index in the male and female
populations. FRS is determined by age, sex, LDL, HDL, TG, the smoking
status, and the presence of hypertension, and diabetes; therefore, the
standard multiple linear regression analyses for LAB were performed
using these factors as independent variables to evaluate the most inﬂu-
ential factors for LAB and sLOX-1. As shown in Table 2, among these var-
iables, the current smoking status and LDL were positively associated
with LAB, and HDL was negatively associated with LAB. The goodness
of ﬁt for the regression models was signiﬁcant in the multiple linear re-
gression analysis although adjusted the R2 of the regression model was
14.5%. The estimated VIFs indicated that therewas little evidence for the
existence of collinearity. On the other hand, sLOX-1 was not associated
with any of these variables except the presence of DM.
Fig. 1. A histogram for LOX-Index (A) and log-converted LOX-Index (B) in men and women. After log conversion, the LOX-index had normal distribution (Kolmogorov–Smirnov test:
p b 0.001 for LOX-Index and p = 0.200 for log-converted LOX-Index).
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Among the enrolled subjects, 331 participants agreed to an evalua-
tion of their mental status using SDS. There was no relationship be-
tween the log-converted LOX-Index and SDS scores as shown in Fig. 3.4. Discussion
LOX-Index which is the product of LAB and sLOX-1, reﬂects the bio-
logical activity of LOX-1 ligands. It has been reported that the
multivariable-adjusted hazard ratio for ischemic stroke and myocardial
infarction from the second to top quartile of LOX-Index was three- and
two-fold higher, respectively, than that for the bottom quartile after
multivariable adjustment in a community-based cohort study, respec-
tively [6]. On the other hand, FRS is a multivariable statistical model
that uses age, sex, smoking history, BP, LDL-C, HDL-C, and blood glucose
levels or history of diabetes to estimate coronary event risk among indi-
viduals without previously diagnosed coronary artery disease, and this
risk stratiﬁcation has been widely recommended [13]. In the presentcross-sectional investigation, we observed that LOX-Index was signiﬁ-
cantly associated with the 10-year risk of FRS. This result strongly sup-
ports that LOX-Index is a predictor for CVD; therefore, LOX-Index is a
comprehensive marker for the evaluation of the status of multiple risk
factors.
The multiple linear regression analyses showed that the current
smoking status, LDL, and HDL were associated with LAB. Recently,
Wakabayashi et al. reported that the smoking status was one of the de-
terminants of the LAB in healthy men [14]. Their ﬁndings were consis-
tent with our results. Takanabe-Mori et al. also demonstrated that the
sLOX-1 levels had a signiﬁcantly positive relationship with the
smoking-related parameters, such as the daily consumption of tobacco,
or the log-transformed expired air carbon monoxide concentrations
[15]. Therefore, the biological activity of LOX-1 was associated with
the smoking status. In the present study, sLOX-1 was only weakly asso-
ciated with the presence of diabetes. Previous investigations have dem-
onstrated that sLOX-1 was associated with acute coronary syndrome
[16]. It has been proposed that sLOX-1 was a biomarker for the acute
phase of acute coronary syndrome. Furthermore, sLOX-1 was also
strongly associated with inﬂammation. It is conceivable that the levels
Fig. 2. The relationship between the 10-year risk of FraminghamRisk Scores and log-converted LOX-Index. Therewas a signiﬁcant positive correlation between the 10-year risk of FRS and
log-converted LOX-Index in the male and female populations.
Table 2
Multiple regression analysis of log-converted LAB and sLOX-1.
LAB (log-converted) (R2 = 14.5%) sLOX-1 (log-converted) (R2 = 1.4%)
B 95%CI β p-Value VIF B 95%CI β p-Value VIF
Age 0.001 0.000 to 0.002 0.062 0.197 1.213 0.000 −0.002 to 0.001 −0.021 0.666 1.213
Sex −0.012 −0.033 to 0.009 −0.057 0.257 1.292 −0.005 −0.036 to 0.025 −0.019 0.729 1.292
LDL 0.001 0.001 to 0.001 0.249 b0.001* 1.109 0.000 0.000 to 0.001 0.025 0.619 1.109
HDL −0.001 0.002 to 0.000 −0.165 0.001* 1.502 0.000 −0.001 to 0.001 0.048 0.403 1.502
TG(log) −0.075 −0.120 to−0.030 −0.172 1.148 1.452 −0.004 0.071 to 0.063 −0.007 0.907 1.452
DM 0.002 −0.028 to 0.032 0.007 0.888 1.155 0.052 0.007 to 0.096 0.116 0.023* 1.155
Smoking 0.073 0.043 to 0.103 0.218 b0.001* 1.102 −0.010 −0.055 to 0.034 −0.023 0.646 1.102
HT 0.019 −0.005 to 0.042 0.078 0.114 1.244 0.000 −0.035 to 0.034 −0.001 0.989 1.244
B: coefﬁcient, β: Standardized coefﬁcient, VIF: variance inﬂation factor, LDL: low-density lipoprotein, HDL: high-density lipoprotein, TG: triglyceride, DM: diabetes mellitus, HT:
hypertension.
* p value of b 0.05 was considered statistically signiﬁcant.
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chronic states. Since LAB reﬂected the state of dyslipidemia or smoking,
LOX-Index could assess the cardiovascular risk from both side, that is,
acute and chronic status.Fig. 3. The relationship between the SDS and the log-converted LOX-Index. There was no
signiﬁcant relationship between SDS and the log-converted LOX-Index. The calciﬁcation of
health condition using the SDS and LOX-Index. It was based upon the presence or absence
of cardiovascular risks and depression.Previous investigations indicate a possibility that mental stress
might be associated with oxidative stress. There was no signiﬁcant
association between LOX-Index and the SDS sores in the present inves-
tigation. However, a simultaneous evaluation of LOX-Index and SDS
could be used to classify the subjects on the basis of two different
aspects, oxidative and mental stress. The subjects with SDS scores
over 40 points were deﬁned as being depressed and those with the
log-converted LOX-Index over 3.0 were deﬁned as having cardiovascu-
lar risk due to oxidative stress according to the previous investigation.
Therefore, all subjects were divided into four subsets as shown in
Fig. 3. Subset 3 represented thosewith neither oxidative stress normen-
tal stress; subset 4 consisted of subjects with mental stress, but without
oxidative stress; subset 1 consisted of subjects with oxidative stress, but
without mental stress; subset 2 consisted of subjects with oxidative
stress and mental stress. Thus, this classiﬁcation system could contrib-
ute to the risk assessment for CVD and could help guide individual
subjects.
Recent progress in pharmacotherapy has achieved a drastic decrease
in the incidence of CVD. It has been established that statins can prevent
the primary and secondary onsets of CVD. Further, as observed in a pre-
vious study, the combination of statins and eicosapentaenoic acids de-
creased the incidence of major coronary events by 19% in Japanese
patients with a history of CAD. However, these powerful medications
cannot completely eliminate CVD [17]. Therefore, signiﬁcant residual
cardiovascular risk remains even after the optimum treatment of
7N. Inoue et al. / IJC Metabolic & Endocrine 12 (2016) 3–7dyslipidemia. This residual risk depends upon several undetermined
factors. Given the comprehensive signiﬁcance, LOX-Index-guided ther-
apeutic approach might lead to the resolution of the residual risk.
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